Cytokinetics Publishes Phase II Evidence Of Effect Study Of CK-2017357

6/12/2012 7:48 AM ET

Cytokinetics, Inc. (CYTK: Quote) announced the publication of its Phase II Evidence of Effect clinical study of CK-2017357, an orally bioavailable fast skeletal muscle troponin activator, in patients with amyotrophic lateral sclerosis, or ALS.

The results showed that single oral doses of 250 mg and 500 mg of CK-2017357 appeared safe and well-tolerated in patients with ALS that were studied. In addition, measures of muscle endurance appeared to be improved in a dose-related fashion in patients who received CK-2017357. Also, patients who received CK-2017357, and their investigators, perceived a global benefit on treatment.

The company noted that data from the study, which compared single doses of CK-2017357 to placebo, informed the design of subsequent studies conducted by it which have assessed the safety and tolerability of CK-2017357 in other dosing regimens.

Click here to receive FREE breaking news email alerts for Cytokinetics Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

<<Previous 165 Articles Next>>

Editors Pick

Fed Concerns Contribute To Lackluster Session On Wall Street - U.S. Commentary

There was a mixed performance on Wall Street on Friday. Shares suffered an early decline, as investors continued to express worries about the Federal Reserve. A recovery through the rest of the day allowed the Dow to edge into positive territory by the close. The Nasdaq and S&P 500 posted fractional losses.

Stocks Come Under Pressure Amid Worries About The Fed - U.S. Commentary

Stocks have shown a notable move to the downside in early trading on Friday amid lingering concerns about the outlook for the Federal Reserve's asset purchase program. The major averages have slid firmly into negative territory, adding to the modest losses posted in the previous session. The major averages are currently posting notable losses, near their lows for the young session.

U.S. Durable Goods Orders Rise 3.3% In April, More Than Expected

After reporting a sharp drop in new orders for manufactured durable goods in the previous month, the Commerce Department released a report on Friday showing that durable goods orders rebounded by more than anticipated in the month of April. The report said durable goods orders surged up by 3.3 percent in April after tumbling by a revised 5.9 percent in March.